Skip to main content
Erschienen in: Neurocritical Care 1/2022

07.07.2021 | Original work

Desmopressin Administration and Impact on Hypertonic Saline Effectiveness in Intracranial Hemorrhage

verfasst von: Emily Bowers, Eric Shaw, William Bromberg, Audrey Johnson

Erschienen in: Neurocritical Care | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Desmopressin improves hemostasis through the release of factor VIII, von Willebrand factor, and tissue plasminogen activator, and increases platelet adhesion. Neurocritical Care guidelines recommend consideration of desmopressin in antiplatelet-associated intracranial hemorrhage. Studies supporting its use have not evaluated the potential impact of desmopressin on serum sodium levels in patients receiving hypertonic saline therapy. The purpose of this study was to assess the impact of desmopressin on sodium levels and hypertonic saline effectiveness in intracranial hemorrhage.

Methods

This was a single center retrospective observational chart review. Patients were included in the desmopressin group if they were diagnosed with intracranial hemorrhage, administered desmopressin, and received hypertonic saline infusion. Patients in the hypertonic saline alone group were then matched 1:1 to the patients in the desmopressin group. The primary end point was the effect of desmopressin on reaching a sodium goal of 145–155 mEq/L. The secondary end points included intensive care unit and hospital length of stay, change in sodium, time to reach sodium goal, thrombotic events, mortality, and a composite of increased cerebral edema, hematoma expansion, midline shift, herniation, need for neurosurgical intervention, and neurologic decompensation.

Results

Of 112 patients screened, 25 patients met inclusion criteria for the desmopressin group, and 25 patients were matched with patients in the hypertonic saline alone group. The percentage of patients who reached goal sodium in the desmopressin group compared with hypertonic saline alone was similar (80% vs. 88%, respectively). There were no differences in the secondary end points. In the subgroup analysis, patients in the hypertonic saline group met the predefined sodium goal of 150–155 mEq/L within 48 h more often than those in the desmopressin group (82% vs. 60%, respectively, p = 0.042).

Conclusions

The use of desmopressin in intracranial hemorrhage does not appear to negatively impact the ability for patients to reach goal sodium of 145–155 mEq/L. However, in patients with higher sodium goals, desmopressin may decrease hypertonic saline effectiveness.
Literatur
1.
Zurück zum Zitat Chan S, Hemphill JC. Critical care management of intracerebral hemorrhage. Crit Care Clin. 2014;30(4):699–717.CrossRef Chan S, Hemphill JC. Critical care management of intracerebral hemorrhage. Crit Care Clin. 2014;30(4):699–717.CrossRef
2.
Zurück zum Zitat Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2015;46(7):2032–60.CrossRef Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2015;46(7):2032–60.CrossRef
3.
Zurück zum Zitat Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009;40(7):2398–401.CrossRef Naidech AM, Jovanovic B, Liebling S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009;40(7):2398–401.CrossRef
4.
Zurück zum Zitat Caso V, Paciaroni M, Venti M, et al. Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovasc Dis. 2007;24(2–3):215–8.CrossRef Caso V, Paciaroni M, Venti M, et al. Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovasc Dis. 2007;24(2–3):215–8.CrossRef
5.
Zurück zum Zitat Creutzfeldt CJ, Weinstein JR, Longstreth WT, Becker KJ, Mcpharlin TO, Tirschwell DL. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2009;18(3):221–8.CrossRef Creutzfeldt CJ, Weinstein JR, Longstreth WT, Becker KJ, Mcpharlin TO, Tirschwell DL. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2009;18(3):221–8.CrossRef
6.
Zurück zum Zitat Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary: a statement for healthcare professionals from the neurocritical care society and the society of critical care medicine. Crit Care Med. 2016;44(12):2251–7.CrossRef Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary: a statement for healthcare professionals from the neurocritical care society and the society of critical care medicine. Crit Care Med. 2016;44(12):2251–7.CrossRef
7.
Zurück zum Zitat Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus. 2011;9(4):377–82.PubMedPubMedCentral Franchini M, Lippi G. The use of desmopressin in acquired haemophilia A: a systematic review. Blood Transfus. 2011;9(4):377–82.PubMedPubMedCentral
8.
Zurück zum Zitat Balasubramanian L, Boggio L, Foiles N, et al. Effectiveness of DDAVP in Von Willebrand’s Disease. Blood. 2004;104(11):4031.CrossRef Balasubramanian L, Boggio L, Foiles N, et al. Effectiveness of DDAVP in Von Willebrand’s Disease. Blood. 2004;104(11):4031.CrossRef
9.
Zurück zum Zitat Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007;3(3):138–53.CrossRef Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol. 2007;3(3):138–53.CrossRef
10.
Zurück zum Zitat Huang WY, Saver JL, Wu YL, Lin CJ, Lee M, Ovbiagele B. Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis. JAMA Neurol. 2019;76(8):906–14.CrossRef Huang WY, Saver JL, Wu YL, Lin CJ, Lee M, Ovbiagele B. Frequency of intracranial hemorrhage with low-dose aspirin in individuals without symptomatic cardiovascular disease: a systematic review and meta-analysis. JAMA Neurol. 2019;76(8):906–14.CrossRef
11.
Zurück zum Zitat Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care. 2016;24(1):6–46.CrossRef Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care. 2016;24(1):6–46.CrossRef
12.
Zurück zum Zitat Wagner I, Hauer EM, Staykov D, et al. Effects of continuous hypertonic saline infusion on perihemorrhagic edema evolution. Stroke. 2011;42(6):1540–5.CrossRef Wagner I, Hauer EM, Staykov D, et al. Effects of continuous hypertonic saline infusion on perihemorrhagic edema evolution. Stroke. 2011;42(6):1540–5.CrossRef
13.
Zurück zum Zitat Juul KV, Bichet DG, Nørgaard JP. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine. 2011;40(1):67–74.CrossRef Juul KV, Bichet DG, Nørgaard JP. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine. 2011;40(1):67–74.CrossRef
14.
Zurück zum Zitat Kuramatsu JB, Bobinger T, Volbers B, et al. Hyponatremia is an independent predictor of in-hospital mortality in spontaneous intracerebral hemorrhage. Stroke. 2014;45(5):1285–91.CrossRef Kuramatsu JB, Bobinger T, Volbers B, et al. Hyponatremia is an independent predictor of in-hospital mortality in spontaneous intracerebral hemorrhage. Stroke. 2014;45(5):1285–91.CrossRef
15.
Zurück zum Zitat Ozgönenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J. 2007;83(977):159–63.CrossRef Ozgönenel B, Rajpurkar M, Lusher JM. How do you treat bleeding disorders with desmopressin? Postgrad Med J. 2007;83(977):159–63.CrossRef
16.
Zurück zum Zitat Kim DY, O’leary M, Nguyen A, et al. The effect of platelet and desmopressin administration on early radiographic progression of traumatic intracranial hemorrhage. J Neurotrauma. 2015;32(22):1815–21.CrossRef Kim DY, O’leary M, Nguyen A, et al. The effect of platelet and desmopressin administration on early radiographic progression of traumatic intracranial hemorrhage. J Neurotrauma. 2015;32(22):1815–21.CrossRef
17.
Zurück zum Zitat Kapapa T, Röhrer S, Struve S, et al. Desmopressin acetate in intracranial haemorrhage. Neurol Res Int. 2014;2014:298767.CrossRef Kapapa T, Röhrer S, Struve S, et al. Desmopressin acetate in intracranial haemorrhage. Neurol Res Int. 2014;2014:298767.CrossRef
18.
Zurück zum Zitat Harrois A, Anstey JR, Taccone FS, et al. Serum sodium and intracranial pressure changes after desmopressin therapy in severe traumatic brain injury patients: a multi-centre cohort study. Ann Intensive Care. 2019;9(1):99.CrossRef Harrois A, Anstey JR, Taccone FS, et al. Serum sodium and intracranial pressure changes after desmopressin therapy in severe traumatic brain injury patients: a multi-centre cohort study. Ann Intensive Care. 2019;9(1):99.CrossRef
19.
Zurück zum Zitat Feldman EA, Meola G, Zyck S, et al. Retrospective assessment of desmopressin effectiveness and safety in patients with antiplatelet-associated intracranial hemorrhage. Crit Care Med. 2019;47(12):1759–65.CrossRef Feldman EA, Meola G, Zyck S, et al. Retrospective assessment of desmopressin effectiveness and safety in patients with antiplatelet-associated intracranial hemorrhage. Crit Care Med. 2019;47(12):1759–65.CrossRef
20.
Zurück zum Zitat Naidech AM, Maas MB, Levasseur-franklin KE, et al. Desmopressin improves platelet activity in acute intracerebral hemorrhage. Stroke. 2014;45(8):2451–3.CrossRef Naidech AM, Maas MB, Levasseur-franklin KE, et al. Desmopressin improves platelet activity in acute intracerebral hemorrhage. Stroke. 2014;45(8):2451–3.CrossRef
Metadaten
Titel
Desmopressin Administration and Impact on Hypertonic Saline Effectiveness in Intracranial Hemorrhage
verfasst von
Emily Bowers
Eric Shaw
William Bromberg
Audrey Johnson
Publikationsdatum
07.07.2021
Verlag
Springer US
Erschienen in
Neurocritical Care / Ausgabe 1/2022
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-021-01277-2

Weitere Artikel der Ausgabe 1/2022

Neurocritical Care 1/2022 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.